Corcept Therapeutics And Its Real Value

Luis Alvarez/DigitalVision via Getty Images
In June, Corcept Therapeutics (NASDAQ:CORT) announced a settlement with Sun Pharmaceutical which will keep Sun from producing a generic version of Korlym until 2034. Sun is one of several companies Corcept has…

Click here to view the original article.